The ITFoM consortium, coordinated by Prof Dr Hans Lehrach from the Max Planck Institute for Molecular Genetics in Berlin, will discuss a ten years research program to create the ‘virtual patient’ model and to submit this proposal to the European Commission in the frame of the FET flagship program by the end of April 2012.
The vision of the ITFoM project is to build a personalised patient model, a ‘virtual patient‘. This ‘virtual patient’ will support clinicians and general practitioners in their decision-making for medical therapy, allowing them to choose the optimal treatment for each individual and predict future health risks. The basis for the ‘virtual patient’ model is data pertaining to the genetic make-up of an individual and data on their protein and metabolite levels, which are used as indicators for the health status of a patient. These molecular data will be combined in the model with anatomical and physiological data, and also with information about the life styles and environment of each patient. Decisions on specific medical treatments for patients will be based on data analysed by the model. ‘Virtual patients’ will support medical practitioners in choosing drugs with the optimal effect on the patient, and will drastically reduce unwanted or even harmful side-effects of drugs.
Media enquiries:
ITFoM Managing Office
Max Planck Institute for Molecular Genetics
Ihnestr. 63-73
14195 Berlin
Germany
Tel: +49 30 8413 1614
Email: itfom@molgen.mpg.de; webpage: www.itfom.eu